▶ 調査レポート

ヒト胚性幹細胞の世界市場2020-2025

• 英文タイトル:Human Embryonic Stem Cells Market - Growth, Trends, and Forecast (2020 - 2025)

Mordor Intelligenceが調査・発行した産業分析レポートです。ヒト胚性幹細胞の世界市場2020-2025 / Human Embryonic Stem Cells Market - Growth, Trends, and Forecast (2020 - 2025) / D0MOR-NV059資料のイメージです。• レポートコード:D0MOR-NV059
• 出版社/出版日:Mordor Intelligence / 2020年9月
• レポート形態:英文、PDF、100ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥442,000 (USD4,250)▷ お問い合わせ
  Team User¥494,000 (USD4,750)▷ お問い合わせ
  Corporate License¥624,000 (USD6,000)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、ヒト胚性幹細胞の世界市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、技術スナップショット、用途別(再生医療、幹細胞生物学研究、組織工学、毒性検査)分析、地域別分析、競争状況、市場機会・将来分析などを整理しました。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・技術スナップショット
・ヒト胚性幹細胞の世界市場規模:用途別(再生医療、幹細胞生物学研究、組織工学、毒性検査)
・ヒト胚性幹細胞の世界市場規模:地域別
・競争状況
・市場機会・将来分析

The government funding for the development of regenerative medicine has been increasing in most developed countries, because of its applications in organ transplantation, tissue engineering, and various other applications. In the United States, two major government agencies, National Institutes of Health (NIH) and California Institute of Regenerative Medicine (CIRM), fund almost all the translational researches and regenerative medicine development in the country. It is estimated that the United States government invests around USD 800-900 million every year in stem cell research. Additionally, other factors such as the high prevalence of cardiac and malignant diseases, and rising demand for regenerative medicines are expected to drive the market.

[Key Market Trends]
Stem Cell Biology Research Segment is Expected to Show Better Growth in the Forecast Years
Based on the application, it is segmented into regenerative medicine, stem cell biology research, tissue engineering, and toxicology testing. Stem cell biology research will show better growth, owing to the high prevalence of cardiac and malignant diseases. An article published by the ISSCR (International Society for Stem Cell Research) reported that the stem cells hold potential for the treatment of Parkinson’s disease in humans. Recently, one of the market players, International Stem Cell Corporation (ISCO), received the patent covering methods for generating HLA homozygous parthenogenetic human stem cell lines from unfertilized eggs. The patent was issued in Australia. Furthermore, to boost the pace of stem cell research, the government is providing funding opportunities to researchers. Thus, owing to these factors, the market studied is expected to witness a high growth rate over the forecast period.

[North America Dominates the Human Embryonic Stem Cells Market]
The human embryonic stem cells market is expected to dominate in the North America region owing to extensive research activities, along with high burden of chronic diseases and genetic disorders in the region. The United States also shows a high incidence of other diseases, such as diabetes, heart disease, renal failure, and osteoporosis. Human embryonic stem cells have high potential for use in treatment and may become a standard of care for these diseases. Additionally, the FDA has approved clinical trials, which indicated the use of stem cells. Hence, these factors are expected to influence the growth of the human embryonic stem cells market over the forecast period.

[Competitive Landscape]
The global players into the human embryonic stem cells market are Astellas Pharma Inc, PeproTech Inc, Lineage Cell Therapeutics Inc, Merck KGaA, PromoCell GmbH, STEMCELL Technologies Inc, Thermo Fisher Scientific and ViaCyte, Inc.

[Reasons to Purchase this report]
• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

レポート目次

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Prevalence of Cardiac and Malignant Diseases
4.2.2 Rising Demand for Regenerative Medicines
4.2.3 Increasing Support from Governments and Government and Private Institutions
4.3 Market Restraints
4.3.1 High Cost of the Procedure
4.3.2 Stringent Regulatory Guidelines
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Application
5.1.1 Regenerative Medicine
5.1.2 Stem Cell Biology Research
5.1.3 Tissue Engineering
5.1.4 Toxicology Testing
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Rest of World
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Astellas Pharma Inc
6.1.2 PeproTech Inc
6.1.3 Lineage Cell Therapeutics Inc
6.1.4 Merck KGaA
6.1.5 PromoCell GmbH
6.1.6 STEMCELL Technologies Inc
6.1.7 Thermo Fisher Scientific
6.1.8 ViaCyte, Inc.
6.1.9 Takara Bio Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS